Equities Analysts Issue Forecasts for NRXP Q3 Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Equities researchers at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of NRx Pharmaceuticals in a research note issued on Monday, September 8th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.08) for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2025 earnings at $0.03 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.11 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.11 EPS, FY2027 earnings at $2.53 EPS, FY2028 earnings at $5.00 EPS and FY2029 earnings at $5.49 EPS.

Several other equities analysts have also recently weighed in on NRXP. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. BTIG Research restated a “buy” rating on shares of NRx Pharmaceuticals in a report on Monday, August 25th. Finally, D. Boral Capital restated a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $34.50.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP opened at $3.15 on Wednesday. The stock has a market capitalization of $62.40 million, a PE ratio of -1.41 and a beta of 1.63. The business has a 50 day simple moving average of $2.82 and a two-hundred day simple moving average of $2.55. NRx Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Monday, August 18th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.67).

Institutional Investors Weigh In On NRx Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Anson Funds Management LP raised its holdings in shares of NRx Pharmaceuticals by 535.1% in the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock worth $2,417,000 after buying an additional 993,401 shares during the period. Geode Capital Management LLC raised its holdings in shares of NRx Pharmaceuticals by 27.9% in the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after buying an additional 37,598 shares during the period. Millennium Management LLC purchased a new stake in shares of NRx Pharmaceuticals in the fourth quarter worth approximately $61,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of NRx Pharmaceuticals in the fourth quarter worth approximately $56,000. 4.27% of the stock is owned by institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.